• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy.抗磷脂酶 A2 受体抗体滴度及其亚类在特发性膜性肾病中的变化。
J Am Soc Nephrol. 2012 Oct;23(10):1735-43. doi: 10.1681/ASN.2012030242. Epub 2012 Sep 6.
2
M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.M型磷脂酶A2受体作为特发性膜性肾病的靶抗原
N Engl J Med. 2009 Jul 2;361(1):11-21. doi: 10.1056/NEJMoa0810457.
3
Anti-Phospholipase A2 Receptor 1 and Anti-Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study.抗磷脂酶 A2 受体 1 抗体和抗胱氨酸丰富域抗体在膜性肾病中的识别作用及利妥昔单抗疗效:一项前瞻性队列研究。
Am J Kidney Dis. 2024 May;83(5):588-600.e1. doi: 10.1053/j.ajkd.2023.10.013. Epub 2023 Dec 25.
4
Validation of a phospholipase A2 receptor antibody ELISA in an Australian cohort with membranous glomerulonephritis.澳大利亚膜性肾小球肾炎队列中磷脂酶A2受体抗体酶联免疫吸附测定的验证
Pathology. 2016 Apr;48(3):242-6. doi: 10.1016/j.pathol.2016.02.001. Epub 2016 Mar 8.
5
Anti-phospholipase A₂ receptor antibodies correlate with clinical status in idiopathic membranous nephropathy.抗磷脂酶 A₂ 受体抗体与特发性膜性肾病的临床状态相关。
Clin J Am Soc Nephrol. 2011 Jun;6(6):1286-91. doi: 10.2215/CJN.07210810. Epub 2011 Apr 7.
6
Anti-Phospholipase A2 Receptor (Anti-PLA2R) Antibody in Diagnosis and Treatment of Idiopathic Membranous Nephropathy: A Single-Center Observational Study in China.抗磷脂酶 A2 受体(Anti-PLA2R)抗体在特发性膜性肾病诊断和治疗中的作用:中国单中心观察性研究。
Med Sci Monit. 2019 Dec 9;25:9364-9368. doi: 10.12659/MSM.917732.
7
Clinical features, course and prognosis of idiopathic membranous nephropathy depending on the presence of antibodies against M-type phospholipase A2 receptor.根据抗M型磷脂酶A2受体抗体的存在情况,特发性膜性肾病的临床特征、病程及预后
Nefrologia. 2015;35(5):479-86. doi: 10.1016/j.nefro.2015.05.026. Epub 2015 Jul 7.
8
Anti-Phospholipase A2 Receptor Antibody as Prognostic Indicator in Idiopathic Membranous Nephropathy.抗磷脂酶A2受体抗体作为特发性膜性肾病的预后指标
Am J Nephrol. 2015;42(3):250-7. doi: 10.1159/000440983. Epub 2015 Oct 20.
9
Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN).抗 M 型磷脂酶 A2 受体(PLA2R)自身抗体在特发性膜性肾病(IMN)监测疾病活动中的临床意义。
Autoimmun Rev. 2016 Feb;15(2):146-54. doi: 10.1016/j.autrev.2015.10.004. Epub 2015 Oct 23.
10
Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy.新型 ELISA 法检测膜性肾病中血栓素 A2 型 1 结构域包含蛋白 7A 自身抗体。
Kidney Int. 2019 Mar;95(3):666-679. doi: 10.1016/j.kint.2018.10.024.

引用本文的文献

1
The Presence of Risk and Protective HLA-DQ Haplotype Combinations and PLA2R1 Risk SNP in Hungarian Patients with Membranous Nephropathy.匈牙利膜性肾病患者中风险与保护性HLA-DQ单倍型组合及PLA2R1风险单核苷酸多态性的存在情况
Int J Mol Sci. 2025 Sep 4;26(17):8621. doi: 10.3390/ijms26178621.
2
Clinical outcomes of immunosuppressive therapy in patients with seronegative anti-PLA2R antibodies and PLA2R-related membranous nephropathy.血清阴性抗PLA2R抗体及PLA2R相关膜性肾病患者免疫抑制治疗的临床结局
Clin Exp Nephrol. 2025 Jul 20. doi: 10.1007/s10157-025-02731-7.
3
Clinical uptake of an antigen-based approach to membranous nephropathy: a survey of general nephrologists and glomerular disease experts.基于抗原的膜性肾病治疗方法的临床应用:对普通肾脏病专家和肾小球疾病专家的调查
J Nephrol. 2025 Jun 11. doi: 10.1007/s40620-025-02313-6.
4
Newer B-cell and plasma-cell targeted treatments for rituximab-resistant patients with membranous nephropathy.针对利妥昔单抗耐药的膜性肾病患者的新型B细胞和浆细胞靶向治疗方法。
Clin Kidney J. 2025 Mar 21;18(5):sfaf088. doi: 10.1093/ckj/sfaf088. eCollection 2025 May.
5
Telitacicept and Tacrolimus Synergy in Managing Refractory Primary Membranous Nephropathy: Case Insights.泰它西普与他克莫司联合治疗难治性原发性膜性肾病:病例分析
Am J Case Rep. 2025 Apr 23;26:e946727. doi: 10.12659/AJCR.946727.
6
Predicting Remission in Antiphospholipase A2 Receptor Antibody-Associated Membranous Nephropathy: A Secondary Analysis of the GEMRITUX, MENTOR, and STARMEN Trials.预测抗磷脂酶A2受体抗体相关膜性肾病的缓解:GEMRITUX、MENTOR和STARMEN试验的二次分析
Clin J Am Soc Nephrol. 2025 Apr 14;20(6):854-865. doi: 10.2215/CJN.0000000694.
7
Detection and prognostic relevance of PLA2R epitopes in idiopathic membranous nephropathy: a simultaneous quantitative multiplex suspension array detection method.特发性膜性肾病中PLA2R表位的检测及其预后相关性:一种同步定量多重悬浮阵列检测方法
Clin Kidney J. 2025 Jan 13;18(3):sfaf010. doi: 10.1093/ckj/sfaf010. eCollection 2025 Mar.
8
Designing Clinical Trials for the Treatment of Membranous Nephropathy in the Anti-Phospholipase A2 Receptor 1 Era: Results of a NephCure Membranous Nephropathy Workshop.抗磷脂酶A2受体1时代膜性肾病治疗的临床试验设计:NephCure膜性肾病研讨会结果
Glomerular Dis. 2025 Mar 14;5(1):133-141. doi: 10.1159/000544808. eCollection 2025 Jan-Dec.
9
Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy.评估非扎妥单抗在抗磷脂酶A2受体自身抗体阳性原发性膜性肾病中的安全性和有效性的1b/2a期研究
Kidney Int Rep. 2024 Jun 20;9(9):2635-2647. doi: 10.1016/j.ekir.2024.06.018. eCollection 2024 Sep.
10
Therapeutic targets in membranous nephropathy: plasma cells and complement.膜性肾病的治疗靶点:浆细胞与补体
Clin Kidney J. 2024 Aug 13;17(9):sfae243. doi: 10.1093/ckj/sfae243. eCollection 2024 Sep.

本文引用的文献

1
Anti-PLA₂R antibodies in membranous nephropathy: ready for routine clinical practice?膜性肾病中的抗磷脂酶A₂受体抗体:准备好用于常规临床实践了吗?
Neth J Med. 2012 Apr;70(3):109-13.
2
Low-molecular-weight proteins as prognostic markers in idiopathic membranous nephropathy.低分子量蛋白质作为特发性膜性肾病的预后标志物。
Clin J Am Soc Nephrol. 2011 Dec;6(12):2846-53. doi: 10.2215/CJN.04020411.
3
Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy.利妥昔单抗诱导的抗 PLA2R 自身抗体耗竭可预测膜性肾病的反应。
J Am Soc Nephrol. 2011 Aug;22(8):1543-50. doi: 10.1681/ASN.2010111125. Epub 2011 Jul 22.
4
Direct characterization of target podocyte antigens and auto-antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens.直接鉴定人类膜性肾小球肾炎中的靶足细胞抗原和自身抗体:α-烯醇化酶和界线性抗原。
J Proteomics. 2011 Sep 6;74(10):2008-17. doi: 10.1016/j.jprot.2011.05.021. Epub 2011 May 19.
5
An immunofluorescence test for phospholipase-A₂-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis.抗磷脂酶 A₂ 受体抗体的免疫荧光检测及其在膜性肾小球肾炎患者中的临床应用。
Nephrol Dial Transplant. 2011 Aug;26(8):2526-32. doi: 10.1093/ndt/gfr247. Epub 2011 Jun 1.
6
Early-childhood membranous nephropathy due to cationic bovine serum albumin.阳离子牛血清白蛋白导致的儿童期膜性肾病。
N Engl J Med. 2011 Jun 2;364(22):2101-10. doi: 10.1056/NEJMoa1013792.
7
Anti-phospholipase A2 receptor antibody in membranous nephropathy.抗磷脂酶 A2 受体抗体在膜性肾病中的作用。
J Am Soc Nephrol. 2011 Jun;22(6):1137-43. doi: 10.1681/ASN.2010090967. Epub 2011 May 12.
8
Anti-phospholipase A₂ receptor antibodies correlate with clinical status in idiopathic membranous nephropathy.抗磷脂酶 A₂ 受体抗体与特发性膜性肾病的临床状态相关。
Clin J Am Soc Nephrol. 2011 Jun;6(6):1286-91. doi: 10.2215/CJN.07210810. Epub 2011 Apr 7.
9
PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy.膜性肾病中的PLA2R自身抗体和PLA2R肾小球沉积物
N Engl J Med. 2011 Feb 17;364(7):689-90. doi: 10.1056/NEJMc1011678.
10
Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy.特发性膜性肾病中风险 HLA-DQA1 和 PLA(2)R1 等位基因。
N Engl J Med. 2011 Feb 17;364(7):616-26. doi: 10.1056/NEJMoa1009742.

抗磷脂酶 A2 受体抗体滴度及其亚类在特发性膜性肾病中的变化。

Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy.

机构信息

Radboud University Nijmegen Medical Centre, Department of Nephrology, Nijmegen, The Netherlands.

出版信息

J Am Soc Nephrol. 2012 Oct;23(10):1735-43. doi: 10.1681/ASN.2012030242. Epub 2012 Sep 6.

DOI:10.1681/ASN.2012030242
PMID:22956816
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3458465/
Abstract

The phospholipase A(2) receptor (PLA(2)R) is the major target antigen in idiopathic membranous nephropathy. The technique for measuring antibodies against PLA(2)R and the relationship between antibody titer and clinical characteristics are not well established. Here, we measured anti-PLA(2)R (aPLA(2)R) antibody titer and subclass in a well defined cohort of 117 Caucasian patients with idiopathic membranous nephropathy and nephrotic-range proteinuria using both indirect immunofluorescence testing (IIFT) and ELISA. We assessed agreement between tests and correlated antibody titer with clinical baseline parameters and outcome. In this cohort, aPLA(2)R antibodies were positive in 74% and 72% of patients using IIFT and ELISA, respectively. Concordance between both tests was excellent (94% agreement, κ=0.85). Among 82 aPLA(2)R-positive patients, antibody titer significantly correlated with baseline proteinuria (P=0.02). Spontaneous remissions occurred significantly less frequently among patients with high antibody titers (38% versus 4% in the lowest and highest tertiles, respectively; P<0.01). IgG4 was the dominant subclass in the majority of patients. Titers of IgG4, but not IgG1 or IgG3, significantly correlated with the occurrence of spontaneous remission (P=0.03). In summary, these data show high agreement between IIFT and ELISA assessments of aPLA(2)R antibody titer and highlight the pathogenetic role of these antibodies, especially the IgG4 subclass, given the observed relationships between aPLA(2)R titer, baseline proteinuria, and outcome.

摘要

磷脂酶 A(2)受体 (PLA(2)R) 是特发性膜性肾病的主要靶抗原。目前,用于检测抗 PLA(2)R 抗体的技术以及抗体滴度与临床特征之间的关系尚未得到充分确立。在这里,我们使用间接免疫荧光检测(IIFT)和 ELISA 检测,在 117 例明确诊断的特发性膜性肾病和肾病范围蛋白尿的白种人患者队列中,测量抗 PLA(2)R(aPLA(2)R)抗体滴度和亚类,并评估了两种检测方法之间的一致性,以及抗体滴度与临床基线参数和结局的相关性。在该队列中,IIFT 和 ELISA 检测 PLA(2)R 抗体阳性率分别为 74%和 72%。两种检测方法之间的一致性非常好(一致性 94%,κ=0.85)。在 82 例 aPLA(2)R 阳性患者中,抗体滴度与基线蛋白尿显著相关(P=0.02)。高抗体滴度患者的自发缓解发生率明显较低(最低和最高三分位数组分别为 38%和 4%;P<0.01)。大多数患者以 IgG4 为优势亚类。IgG4 滴度,但不是 IgG1 或 IgG3 滴度,与自发缓解的发生显著相关(P=0.03)。总之,这些数据表明 IIFT 和 ELISA 检测 aPLA(2)R 抗体滴度的结果高度一致,并突出了这些抗体,尤其是 IgG4 亚类的致病作用,因为观察到 aPLA(2)R 滴度、基线蛋白尿和结局之间存在相关性。